Share on LinkedInShare on LinkedIn

ARTICLE · 16 OCTOBER 2009

Conditions Imposed on Pfizer & GM Deals as Chinese Merger Control Ramps Up

Mayer Brown
Mayer Brown
Contributor
Mayer Brown

Mayer Brown

Mayer Brown is a leading international law firm positioned to represent the world’s major...

View firm profile
Explore more from Mayer Brown

China's Ministry of Commerce (MOFCOM) has announced two new conditional clearance decisions under the country's Anti-Monopoly Law (AML) merger control system, meaning five deals have now been subject to conditional approval or outright prohibition since the law commenced.

ChinaAntitrust/Competition Law

Originally published 6 October 2009

Keywords: Pfizer, GM Deals, Chinese merger control, MOFCOM, AML, merger control system, Wyeth, Intervet, Akzo Nobel

China's Ministry of Commerce (MOFCOM) has announced two new conditional clearance decisions under the country's Anti-Monopoly Law (AML) merger control system, meaning five deals have now been subject to conditional approval or outright prohibition since the law commenced.

On the basis of statistics published by MOFCOM in July this year, it is now estimated that approximately 8% of all reviewed deals have failed to obtain unconditional clearance1. This is higher than the prevailing pattern of review outcomes in more mature antitrust jurisdictions such as Europe and the U.S.A.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from